Rebecca Li will be speaking at the NIA-DUKE-Alzheimer’s Association Workshop held on March 15-16th sponsored by the National Institute on Aging.
The focus of the talk by Rebecca Li and Katherine Welsh-Bohmer (Duke University School of Medicine) is on how the Vivli platform can be used to access trials in Alzheimer’s Disease. Dr. Welsh-Bohmer will discuss the TOMMORROW trial – a large prevention study in Alzheimer’s Disease – as a specific use case.
“We are thrilled to welcome Bayer as a member of Vivli,” said Rebecca Li, Vivli Executive Director. “We look forward to supporting researchers to request and analyze Bayer’s data securely.”
As a global leader in healthcare and nutrition, Bayer offers innovative products that support efforts to overcome challenges presented by a growing and aging global population by helping to prevent, alleviate and treat diseases.
“We are very excited to join Vivli and the large global community of leading clinical trial sponsors engaged in data sharing. Vivli offers a great opportunity for Bayer to further strengthen our commitments to transparency and data sharing for our clinical trials”, says Sigrid Achenbach, Head of Clinical Trial Transparency at Bayer.
For more information about the conditions for accessing Bayer anonymized data from completed clinical trials, please visit their member page. For additional information about Membership in Vivli, learn more here.
Vivli enthusiastically congratulates Dr. Monica Bertagnolli on her recent appointment as Director of the National Cancer Institute (NCI).
Dr. Bertagnolli has served as a long-time member on the Vivli External Advisory Committee.
“We are glad to see Dr. Monica Bertagnolli take on such an impactful role and we wish her all the best,” said Rebecca Li, Executive Director.
Biden Selects Harvard Professor as National Cancer Institute Director – The Harvard Crimson
Vivli announced that it had reached a new milestone with 100 public disclosures, including many from peer-reviewed journal publications, has just been published using data requested via the Vivli platform.
We are so pleased that we have reached this milestone during the month of our four-year anniversary,” said Rebecca Li, Executive Director. “So much of the hard work belongs to our members and investigators who have made this possible. We are grateful for these continued support and use of the Vivli platform.”
For a list of all publications go to: https://vivli.org/public-disclosures/
Vivli welcomes our newest partner platform as a member, the NIH Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis.
“We are delighted to include the NIH HEAL Initiative as a member of Vivli,” said Rebecca Li, Vivli Executive Director. “Making these valuable studies available for searching on Vivli is helping to ensure that researchers and the public can find and access them along with the other pain and addiction clinical research data on Vivli. Access of these data will drive scientific discovery, research dissemination and adoption to advance human health.”
Virtually every NIH Institute and Center is accelerating research through the NIH HEAL Initiative to address this public health emergency from all angles. A centerpiece effort to achieving HEAL’s mission is the HEAL Data Ecosystem, which aims to transform research data, findings, and publications into a virtual, annotated, searchable catalog where datasets can be analyzed, compared, and combined.
“HEAL-generated data holds the key to helping patients and communities devastated by the opioid crisis, as well as those seeking relief for unmanaged chronic pain that limits all aspects of life. Vivli offers a valuable tool for researchers in HEAL and beyond to access this rich set of data stored in various repositories that meet security and privacy standards – giving HEAL researchers a great option to leverage their data for new discovery and long-term preservation,” said Rebecca Baker, Ph.D., director of the initiative.
For more information about how the NIH HEAL Initiative supports its investigators to share their data on Vivli, please visit their member page. For additional information about Vivli membership, learn more.
Vivli is a non–profit organization working to advance human health through the insights and discoveries gained by sharing and analyzing clinical trial data. It is home to an independent global data-sharing and analytics platform which serves all elements of the international research community.
VIVLI, the Center for Global Clinical Research is seeking a seasoned Project Coordinator to assist with the launch of our global data sharing platform. The opportunity to join a fast-growing start-up environment with a mission-focused non-profit.
Individual must be a self-starter, experienced and able to work independently in a fast-paced start-up environment.
Team Coordination and responsibilities
Comms, Marketing
Salary commensurate with experience.
To apply email hr@vivli.org
VIVLI, the Center for Global Clinical Research is seeking a seasoned Program Manager. Vivli is a mission-focused non-profit. For more information see www.vivliorg.kinsta.cloud
Program Manager (Job Description)
Overall Duties and Responsibilities include the following:
Vivli’s Program Manager has responsibility for:
Ideal Qualifications
To apply, send a cover letter and CV to hr@vivli.org.
Vivli Executive Director, Rebecca Li, will take part in a panel discussion as part of Data Sharing to Accelerate Therapeutic Development for Rare Diseases hosted by Duke and the FDA. Her session will focus on platform analytics tools to support data sharing and drug development for rare diseases.
The Duke-Margolis Center for Health Policy, through a cooperative agreement with the U.S. Food & Drug Administration, is convening a two-day public meeting on August 18th and 19th, to discuss the importance of data sharing for accelerated therapeutic development in rare disease as well as considerations for sustaining and leveraging a robust data sharing infrastructure to support innovative rare disease trial design. The meeting will explore several topics including:
Please see the event page for more details and to register for the event.
Join Vivli, COVID Collaboration Platform (CP) and TransCelerate BioPharma for a discussion of how these organizations are working to support academia, foundations and industry to collaborate and share data for COVID-19 trials.
The webinar will discuss the work that each organization is taking to support their stakeholders to more quickly collaborate, share and analyze COVID-19 data to accelerate science.
The webinar will be hosted on July 9 at 9 am Pacific/12 pm ET/6 pm CET.
Key topics include:
Webinar attendees will have the opportunity to ask questions of the panelists.
Presenters:
Rebecca Li, Vivli
Elizabeth L. Ogburn, Barbara Bierer, COVID Collaboration Platform
Janice Chang, Cara Rinaldi, TransCelerate BioPharma, Inc
d-wise offers anonymization services to studies available on Vivli COVID-19 portal
Breaking News— d-wise and Vivli are partnering to accelerate COVID-19 data sharing. d-wise will waive fees to anonymize COVID-19 studies made available through the Vivli platform. Vivli launched its COVID-19 portal last week and announced it will waive fees to share, archive and access all of its clinical trials related to COVID-19.
“We are deeply grateful by the offers of support we have received to lower the barriers to those conducting COVID-19 clinical trials,” said Rebecca Li, Vivli Executive Director. “Making anonymization as easy as possible for those sharing COVID-19 clinical trials is a vital step forward so that these data can be shared more widely. We are pleased to be able to provide an end-to-end offering for COVID-19 data sharing.”
“Sharing data powers medical innovation. The time is now – we encourage those conducting clinical research to contribute and share data as part of the global response,” said Stephen Baker, Director of Strategic Accounts at d-wise. “d-wise is proud to play its part to accelerate the sharing ecosystem in the fight against COVID-19.”
Vivli is working with d-wise, along with other stakeholders, to share the data from COVID-19 trials.
About d-wise:
d-wise is committed to helping pharmaceutical, biotech, contract research organizations, and medical device companies navigate technology change in pursuit of human health and wellbeing. With deep domain experience in biometrics, software engineering, statistical programming, standards, and change management, d-wise products and services power innovation to accelerate clinical trial data analysis and data sharing.
For questions and inquiries, please contact d-wise at info@d-wise.com or visit www.d-wise.com/transparency.
If you have other ways you can contribute to the COVID-19 effort, please let us know.
The current pandemic represents an opportunity for scientists and partners to work together towards a global response. On March 20, 2020 for sharing of clinical trials. All fees will be waived for sharing and access. Find out more about the process.
Vivli announced the launch of the COVID-19 portal as part of our desire to do our part in response to the global pandemic. We believe this will help us work toward our ultimate vision to advance human health through clinical research data sharing and to respect and honor the contributions of clinical research participants. As we all confront this challenging situation, the time for sharing data and ensuring that we are all doing what we can as a scientific community to advance human health has never been more pressing.
If you or your organization has research data from a COVID-19 related trial to share or wish to connect with Vivli on how your organization can help, please get in touch with us in filling out the form below and we will respond shortly.